Spironolactone Tablet, Film Coated
Product Images NDC 71610-287

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 71610-287). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 50 mg (71610 0287 30)

Bottle Label 50 mg (71610 0287 30)
Label for Spironolactone USP 50 mg film-coated tablets, containing 30 tablets per bottle. The label includes storage instructions and manufacturing details, stating it is made by Intas Pharmaceuticals Limited in Ahmedabad, India, with packaging by Aphena Pharma Solutions in Cookeville, TN. The product is marked for prescription use only.*
FDA Label Image

Bottle Label 100 mg (71610 0288 30)

Bottle Label 100 mg (71610 0288 30)
Spironolactone 100 mg film-coated tablets label showing 30 count. The label indicates storage instructions, manufacturer as Intas Pharmaceuticals Limited in Ahmedabad, India, and the labeler Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN 38506. The product is for prescription use only.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)
A Kaplan-Meier survival plot comparing the probability of an event over time between two groups: one receiving Spironolactone (n=822) and the other receiving a placebo (n=841). The x-axis represents months (0 to 48), and the y-axis represents probability (0 to 1). Spironolactone shows higher survival probability compared to placebo. The graph includes a log-rank p-value of less than 0.001.*
FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)
A forest plot showing hazard ratios (HR) and 95% confidence intervals (CI) for various subgroups analyzed in a clinical study comparing Spironolactone to placebo. Subgroups include age, sex, race, left ventricular ejection fraction (LVEF), heart failure type, NYHA class, diabetes status, serum creatinine levels, creatinine clearance, potassium levels, and use of digoxin, ACE inhibitors, and beta blockers. The plot visually compares treatment effects across these groups.*
FDA Label Image

Chemical Structure (Spironolactone Structure Image)

Chemical Structure (Spironolactone Structure Image)
Chemical structure of spironolactone depicted as a molecular diagram showing its characteristic steroid backbone with attached functional groups including a lactone ring and a thioacetyl substitution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.